background


Product Information:

Bimekizumab

Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .

Cat. No.: EX-A7045    Purity: >98%
Chemical
Chemical structure of Bimekizumab


For research only, Do not use for Human!

SizeUnit Price (US$)StockQuantityOrder
100mgget quoteIn-stock
250mgget quoteIn-stock
500mgget quoteIn-stock


CAS No.1418205-77-2
Purity>98%
Colorcolorless to light yellow
Stateliquid
StoragePlease store the product under the recommended conditions in the Certificate of Analysis.
ShippingShipping with dry ice/ice bag
 
 
Reference:  

[1]. Shah M, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020 Jul;6(2):e001306.

CoACoA of Bimekizumab

KEYWORDS: buy Bimekizumab | Bimekizumab supplier | purchase | cost | manufacturer | order | distributor | buy 1418205-77-2 | 1418205-77-2 supplier